APRETUDE

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

ProphylaxisHIV Infections

27 competitors in Prophylaxis

#DrugCompanyPhaseTrials

1

Lovenox

Sanofi

Approved

132

Eliquis

Bristol-Myers Squibb

Approved

23

Bayer Aspirin

Bayer

Approved

24

Cymbalta

Jazz Pharmaceuticals

Approved

15

Xarelto

WWim Janssens

Approved

46

Coreg

Akero Therapeutics

Approved

47

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

38

Cabenuva

GSK

Phase 3

29

Lovenox

Sanofi

Phase 3

110

Prevymis

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

3Show 17 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Women1 trial

A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories

Completed·GSK·Phase 4·NCT05514509·370 enrolled

Volume1 trial

A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States

Completed·GSK·Phase 4·NCT05374525·287 enrolled

Prophylaxis1 trial

Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs

Recruiting·MMassachusetts General Hospital·Phase 4·NCT07199335·100 enrolled

HIV Infections1 trial

Long-acting HIV Pre-Exposure Prophylaxis Integrated With Community-based Sexual and Reproductive Health in South Africa (LAPIS): A Hybrid (1a) Cluster Randomised Controlled Phase 3B Trial of Effectiveness and Implementation

Recruiting·AAfrica Health Research Institute·Phase 3·NCT06250504·2,052 enrolled

Details

Drug Info

Related News